R13 (7,8-DHF prodrug)
In 2015, Emory licensed its rights to 7,8-dihydoxyflavone prodrugs to Shanghai Braegen Pharmaceutical Company, Ltd. The 7,8-DHF compound is known to function as a potent TrkB agonist, and the 7,8-DHF prodrug increases the compound’s bioavailability and increases activation of the TrkB receptor. Shanghai Braegen is a Chinese-based startup created by faulty Keqiang Ye. The company focuses on developing drugs to treat neurodegenerative disease and is developing the 7,8-DHF prodrug to treat Alzheimer’s Disease.